Search
Now showing items 1-6 of 6
Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories
(Wiley, 2017-01-20)
Over the past few years, treatment options for chronic hepatitis C virus (HCV) infection have evolved dramatically. The current approved interferon-free direct-acting antiviral (DAA) regimens have been shown to be safe and ...
Isolated Intrapulmonary Vascular Dilatations and the Risk of Developing Hepatopulmonary Syndrome in Liver Transplant Candidates.
(Elsevier, 2017-08-01)
BACKGROUND:
The natural history of intrapulmonary vascular dilations (IPVD) and their impact on patient outcomes in the setting of portal hypertension has only been described in small series.
AIMS:
To assess the ...
Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.
(Wiley, 2017-09-01)
Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real-clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV ...
Ombitasvir / paritaprevir / ritonavir / dasabuvir ± ribavirina es segura y efectiva en el HCV - infectados pacientes en una vida real cohorte de América Latina .
(Wiley, 2017-03-29)
Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real-clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV ...
Developing multicenter consortia in liver disease in Latin America: Challenges and opportunities.
(Wiley, 2017-06-07)
The development of consortia has been useful for exploring challenging scenarios and uncharted territories in liver disease treatments. Several consortia already developed in the United States and Europe have become key ...
Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories.
(Wiley, 2017-06-01)
Over the past few years, treatment options for chronic hepatitis C virus (HCV) infection have evolved dramatically. The current approved interferon-free direct-acting antiviral (DAA) regimens have been shown to be safe and ...